REG - hVIVO PLC - Annual Report, Notice of AGM & Directorate Change

hVIVOAnnouncement

12/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250512:nRSL1612Ia&default-theme=true

RNS Number : 1612I  hVIVO PLC  12 May 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Annual Report, Notice of AGM

&

Directorate Change

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and
the world leader in human challenge clinical trials, confirms that the
Company's Annual Report and Accounts for the year ended 31 December 2024 and
the Notice of Annual General Meeting ("AGM") will be posted to shareholders
today.

 

The 2024 Annual Report and Accounts, the Notice of AGM and accompanying form
of proxy are available to download from the Company's website www.hvivo.com
(http://www.hvivo.com) .

 

The Annual General Meeting will be held at the offices of Cavendish Capital
Markets Ltd, 1 Bartholomew Close, London, EC1A 7BL, on 5 June 2025 at 11am
BST.

 

Directorate Change

 

Martin Gouldstone, Non-Executive Director, has informed the Company that he
does not intend to seek re-election to the Board of the Company at the AGM and
will stand down from his position at the conclusion of the AGM. Martin joined
the hVIVO plc Board in June 2022 and is leaving to focus on his other business
interests. The Nominations Committee have identified a new independent
Non-Executive Director who brings significant relevant experience and
expertise, and the Board believes their appointment will add considerable
value to the Company as it executes its strategy. Subject to successful
completion of customary due diligence procedures by the Company's Nominated
Adviser, the formal appointment is expected to be made in advance of the
Company's forthcoming AGM and it is intended that the new NED will chair the
audit committee.

 

As announced on 10 April 2025, since co-founding the business in 2017 and
having been Chair for the past eight years, Cathal Friel has decided not to
seek re-election at the AGM. Mr Friel will continue to serve as Chair until
the conclusion of the AGM. Following the AGM, Dr Elaine Sullivan, the
Company's Senior Independent Non-Executive Director will assume the role of
Interim Chair of the Board until the Company appoints a permanent Chair. The
Nominations Committee is continuing its process to appoint a new Chair and the
Company will announce the results of this process in due course.

 

The Board would like to sincerely thank both Cathal Friel and Martin
Gouldstone for their valuable contribution and leadership during their tenure.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0)20 7220 0500
 Geoff Nash, Camilla Hume, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com

 Paul McManus                                    +44 (0)7980 541 893

 

 

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (Ticker: HVO) is full-service Contract Research
Organisation (CRO) and the global leader in human challenge trials. The
company delivers end-to-end clinical development services to a diverse and
expanding client base, including seven of the world's ten largest biopharma
companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/) brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development Consulting
and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment via
FluCamp (https://flucamp.com/) . Additionally, its five clinical sites support
outpatient Phase II and III trials, ensuring a seamless and efficient pathway
from discovery to late-stage development.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUPUAUAUPAPPB